Comparison of the cyclophosphailiide (C), ara-c (A), topotecan (T), (CAT) regimen to ara-c plus topotecan or idarubicin (I) as initial therapy for patients with adverse abnormal karyotype acute myeloid leukemia (AML).

被引：0
|
作者：
Beran, H [1 ]
Giles, FJ [1 ]
Cortes, JE [1 ]
Thomas, DA [1 ]
Koller, C [1 ]
O'Brien, SM [1 ]
Keating, MJ [1 ]
Freireich, E [1 ]
Kantarjian, HM [1 ]
Estey, E [1 ]
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 1999年 / 94卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4213
引用
收藏
页码：226B / 226B
页数：1
相关论文
共 50 条
  • [41] CYTOSINE-ARABINOSIDE (ARA-C) IN INTERMEDIATE DOSES (IDAC) AS THERAPY FOR PATIENTS (PTS) WITH ACUTE MYELOID-LEUKEMIA (AML)
    ESTEY, EH
    PLUNKETT, WK
    KEATING, MJ
    MCCREDIE, KB
    FREIREICH, EJ
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1988, 29 : 209 - 209
  • [42] Topotecan, Ara-C, cisplatin and prednisolone (TOPOSHAP) for patients with refractory and relapsing lymphomas: Results of a phase I trial
    Coutinho, F
    Manhani, AR
    Velasquez, WS
    del Giglio, A
    ACTA HAEMATOLOGICA, 2004, 112 (03) : 121 - 125
  • [43] Adaptively randomized prospective study of Troxacitabine and Ara-c (A), Troxacitabine and Idarubicin (I), and IA in older patients with unfavorable karyotype AML.
    Giles, F
    Estey, E
    Cortes, J
    Thomas, D
    Ferrajoli, A
    Faderl, S
    Verstovsek, S
    Wathen, K
    O'Brien, S
    Kantarjian, H
    BLOOD, 2002, 100 (11) : 563A - 564A
  • [44] ARA-C AND AMSA FOR TREATMENT OF RELAPSED AND REFRACTORY ACUTE MYELOID-LEUKEMIA
    JAGER, U
    LECHNER, K
    SCHWARZINGER, I
    BETTELHEIM, P
    BOGNAR, H
    GEISSLER, K
    HAAS, O
    HINTERBERGER, W
    KOS, M
    LEITHA, T
    NEUMANN, E
    PANZER, S
    POLLAK, C
    BLUT, 1986, 53 (03): : 145 - 145
  • [45] LOW-DOSE ARA-C(LODAC) IN ACUTE MYELOID-LEUKEMIA
    AMADORI, S
    PETTI, MC
    AVVISATI, G
    SIKOGLOU, N
    MANDELLI, F
    PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, 1984, 25 (MAR): : 185 - 185
  • [46] Interim analysis of cytarabine (ara-C) and cladribine (2-CDA) combination therapy in acute myeloid leukemia (AML).
    Radomski, KM
    Gandhi, V
    Srivastava, DK
    Razzouk, BI
    Behm, FG
    Plunkett, W
    Pui, CH
    Rubnitz, JE
    Ribeiro, RC
    BLOOD, 2000, 96 (11) : 327A - 327A
  • [47] MITOXANTRONE AND ARA-C IN PREVIOUSLY TREATED PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA
    PACIUCCI, PA
    DUTCHER, JP
    CUTTNER, J
    STRAUMAN, JJ
    WIERNIK, PH
    HOLLAND, JF
    LEUKEMIA, 1987, 1 (07) : 565 - 567
  • [48] Combination therapy with aclarubicine, etoposide and Ara-c (AVA) in the treatment of acute myeloid leukemia in the elderly
    Staib, P
    Lathan, B
    Steinmetz, HT
    Schwonzen, M
    KnoppelSchwark, S
    Wickramanayke, PD
    Tesch, H
    Diehl, V
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 852 - 852
  • [49] Mylotarg, liposomal daunorubicin, Ara-C and cyclosporine (MDAC) regimen in patients with relapsed/refractory acute myelogenous leukemia (AML)
    Apostolidou, E
    Cortes, J
    Tsimberidou, AM
    Estey, E
    Kantarjian, H
    Giles, F
    BLOOD, 2002, 100 (11) : 268B - 268B
  • [50] Ara-C, Topotecan, and Gemtuzumab Ozogamicin [ATGO] Is An Effective Induction Regimen for Advanced MDS and Secondary or Relapsed AML: Analysis of a Phase I/II Study
    Langston, Amelia A.
    Murali, Sujatha
    McMillan, Stephanie
    Heffner, Leonard T.
    Lonial, Sagar
    Waller, Edmund K.
    Flowers, Christopher R.
    Kaufman, Jonathan
    McLemore, Morgan L.
    Sinha, Rajni
    Lechowicz, Mary J.
    Khoury, H. Jean
    Winton, Elliott F.
    BLOOD, 2008, 112 (11) : 1247 - 1247
12345